<DOC>
	<DOCNO>NCT02780154</DOCNO>
	<brief_summary>This single center , randomize control human study optimize control human malaria infection ( CHMI ) administer direct venous inoculation ( DVI ) . 36 healthy adult age 18 45 year , randomize one five group inoculate PfSPZ Challenge DVI . Participation duration estimate 2 month , study duration plan 4 month . The primary objective study assess safety reactogenicity PfSPZ Challenge administer DVI use 7G8 NF54 P. falciparum strain .</brief_summary>
	<brief_title>PfSPZ Challenge Non-immune Adults Baltimore , USA</brief_title>
	<detailed_description>The propose study single center , randomize control human study optimize control human malaria infection ( CHMI ) administer direct venous inoculation ( DVI ) . 36 participant randomize one five group inoculate PfSPZ Challenge DVI . All participant recruit healthy adult age 18 45 year . The study duration 4 month , participation duration estimate 2 month . Safety infectivity data collect study product dose-level . Sera collect baseline study day 29 antibody assay . Participants , clinical laboratory investigator blind group allocation . The study primary endpoint reach study day 29 , time interim study report generate . The investigator , sponsor , data statistical analysis team , Sanaria staff meet person teleconference day 43 review infection , pre-patent period , adverse event result . These result make available member International PfSPZ Consortium ( I-PfSPZ-C ) require , regulatory authority , include FDA , facilitate PfSPZ Challenge CHMI study appropriate disclaimer . Participants follow outpatient malaria diagnosis , treatment follow-up study day 57 . Malaria positivity determine qPCR diagnostics microscopy backup . Participants test positive malaria remain negative study day 29 treated oral atovaquone-proguanil . The primary objective study assess safety reactogenicity PfSPZ Challenge administer DVI use 7G8 NF54 P. falciparum strain . Secondary objective 1 ) ass infectivity four escalating dos direct venous inoculation ( DVI ) 7G8 clone comparison establish dose ( 100 % infective ) DVI NF54 strain 2 ) ass time malaria patency escalate dos 7G8 clone compare single dose NF54 strain .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<criteria>1 . Healthy adult age 18 45 year , inclusive 2 . Able willing participate duration study 3 . Able willing provide write ( proxy ) inform consent 4 . Provides informed consent correctly answer great equal 70 % post consent quiz study procedure , available study visit Note : Two attempt permit 5 . Females childbearing potential must agree practice highly effective contraception Note : Contraception must practice 30 day time enrollment least 30 day follow inoculation ( double barrier method ( condom plus foam spermicide , diaphragm plus foam spermicide ) , license intrauterine device ( IUDs ) , intravaginal intra/transdermal oral hormonal method initiate least 30 day inoculation challenge , document surgical sterilization via tubal ligation essure procedure hysterectomy , abstinence vasectomize partner ) . The contraceptive method remain unchanged throughout required period 6 . Is good health , determine vital sign ( heart rate , blood pressure , oral temperature ) ; medical history ; normal laboratory range list Appendix C ; physical examination Note : hemoglobin , white blood cell count , platelet count , glucose ( random ) , serum alanine aminotransferase ( ALT ) , serum creatinine , urine protein urine blood 7 . Agree travel malaria endemic region study day 129 8 . Willing avoid nonstudy relate blood donation screen 3 year ( 45 ) follow P. falciparum challenge 9 . Able understand comply plan study procedure include daily outpatient followup visit begin 5 day inoculation 1 . Any history malaria infection , travel malaria endemic region within 3 month plan date CHMI 2 . History longterm residence ( &gt; 5 year ) area know significant transmission P. falciparum 3 . Positive serology human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) , hepatitis B surface antigen ( HBsAg ) 4 . Positive sickle cell screen test know hemoglobinopathy 5 . Current recent ( within last four week ) treatment parenteral oral corticosteroid ( intranasal inhale steroid acceptable ) , immunosuppressive agent , chemotherapy 6 . Screening laboratory value outside protocolspecified acceptable normal range note Appendix C , except hematuria &gt; 1+ detected menses female . Note : For female menstruate , urinalysis frequently test positive blood indicator poor health status increase risk ; exception include ALT creatinine low limit reference range 7 . Known hypersensitivity component PfSPZ Challenge , atovaquoneproguanil artemetherlumefantrine 8 . History acute chronic medical condition include , limited , disorder liver , kidney , lung , heart , nervous system , metabolic autoimmune/inflammatory condition 9 . History anaphylaxis severe hypersensitivity reaction 10 . Receipt investigational product study day 31 1 plan receipt investigational product study day 157 . 11 . Any condition , opinion investigator , would affect participant 's ability understand comply study protocol would jeopardize participant 's safety right 12 . Use plan use drug antimalarial activity 30 day CHMI Note : Medications antimalarial activity include trimethoprimsulfamethoxazole , azithromycin , erythromycin , tetracycline , doxycycline , minocycline , clindamycin , ciprofloxacin , levofloxacin , norfloxacin rifampin 13 . Planned surgery 30 day CHMI 14 . History drug alcohol abuse within last five year 15 . Receipt blood blood product previous six month donation unit blood within two month screen 16 . History schizophrenia , bipolar disorder psychiatric condition make study compliance difficult Note : Subjects psychoses history suicide attempt gesture 3 year study entry , ongoing risk suicide . 17 . History diabetes mellitus exception pregnancyinduced diabetes resolve 18 . Has evidence increase cardiovascular disease risk ( define &gt; 10 % , 5 year risk ) determine method Gaziano ( 46 ) Note : Risk factor include sex , age ( year ) , systolic blood pressure ( mm Hg ) , smoke status , body mass index ( BMI , kg/mm2 ) , report diabetes status , blood pressure . 19 . Abnormal screen ECG Note : Pathologic Q wave significant STT wave change , leave ventricular hypertrophy , nonsinus rhythm except isolated premature atrial ventricular contraction , right leave bundle branch block , advance AV heart block ( secondary tertiary ) , QT/QTc interval &gt; 450 m 20 . Body mass index ( BMI ) &gt; 40 21 . Known hypersensitivity atovaquoneproguanil artemetherlumefantrine 22 . Anticipated medication use 28day postchallenge period know interact atovaquoneproguanil artemetherlumefantrine Note : Such rifampin , carbamazepine , phenytoin , St. John 's wort , cimetidine , metoclopramide , antacid , kaolin 23 . Personal beliefs prevent receipt human serum albumin 24 . Immunization three vaccine within past month study day 57 CHMI 25 . Previous vaccination candidate malaria vaccine participation CHMI study 26 . History splenectomy 27 . Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 5, 2017</verification_date>
	<keyword>7G8 clone</keyword>
	<keyword>NF54 strain</keyword>
	<keyword>Non-immune</keyword>
	<keyword>PCR</keyword>
	<keyword>PfSPZ Challenge</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>qPCR</keyword>
	<keyword>Sporozoites</keyword>
</DOC>